The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.
 
Yajun Li
No Relationships to Disclose
 
Hong Cen
No Relationships to Disclose
 
Zengjun Li
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Zhiming Li
No Relationships to Disclose
 
Yang Xie
No Relationships to Disclose
 
Haisheng Liu
No Relationships to Disclose
 
Jieping Li
No Relationships to Disclose
 
Ke-Shu Zhou
No Relationships to Disclose
 
Meiyun Fang
No Relationships to Disclose
 
Xiang Li
No Relationships to Disclose
 
Zhengming Jin
No Relationships to Disclose
 
Sanfang Tu
No Relationships to Disclose
 
Yiming Liu
Employment - Jiangsu Hengrui Medicine
 
Dahua Ma
Employment - Jiangsu Hengrui Medicine
 
Wenjun Mao
Employment - Jiangsu Hengrui Medicine
 
Zhenyu Xiao
Employment - Jiangsu Hengrui Medicine
 
Hongxia Zheng
Employment - Jiangsu Hengrui Medicine
 
Yuqin Song
No Relationships to Disclose